World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update.

Authors:
Laranjo L; Lanas F; Sun MC; Chen DA; Hynes L and 14 more

Journal:
Glob Heart

Publication Year: 2024

DOI:
10.5334/gh.1278

PMCID:
PMC10809857

PMID:
38273995

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Glob Heart

Abbreviation: Glob Heart

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Characterization of Non-Ischemic Dilated Cardiomyopathy in a Native Tanzanian Cohort: MOYO Study.
Fundikira LS; Chillo P; Alimohamed MZ and 7 more (2024) - Transparency Score: 3/6
Clinical Outcome of Rheumatic Mitral Valve Repair and Replacement Surgery in Indonesia; A Compariso…
Soesanto AM; Rudiktyo E; Tjubandi A and 4 more (2024) - Transparency Score: 2/6
Edema Index Predicts Mortality in Patients with Chronic Heart Failure: A Prospective, Observational…
Sasmita BR; Zhao Y; Gong M and 2 more (2024) - Transparency Score: 3/6
Heartache and Heartbreak: An Observational and Mendelian Randomization Study.
Cai D; Xia M; Chen X and 6 more (2024) - Transparency Score: 3/6
Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organizati…
Agarwal A; Huffman MD. (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing Interests Fernando Lanas has received speaker honoraria and has served as an advisory board member for Pfizer, Novartis, Bayer, BMS, Boehringer, Astrazeneca, Novo Nordisk. Lale Tokgözoğlu has received honoraria or has been part of advisory boards from Abbott, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Novo Nordisk Pfizer, Recordati, and Sanofi."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025